Ribavirin

Ribavirin is an antiviral medication used in combination with other drugs to treat chronic hepatitis C, a viral infection that affects the liver. It works by inhibiting the replication of the hepatitis C virus, allowing the body’s immune system to fight the infection more effectively.
Ribavirin is typically prescribed in combination with pegylated interferon alfa, another antiviral drug, for a period of 24 to 48 weeks, depending on the severity of the infection and the patient’s overall health. This combination therapy has been shown to significantly reduce the risk of liver-related complications and improve the long-term prognosis for patients with hepatitis C.
In addition to its use in hepatitis C treatment, ribavirin has been used in the past to treat respiratory syncytial virus (RSV) infections in immunocompromised individuals, such as bone marrow transplant recipients and patients with severe combined immunodeficiency. However, its use in this context has largely been replaced by other antiviral medications due to its potential side effects and limited efficacy.
Ribavirin is available in oral and inhaled formulations, and its administration must be closely monitored by a healthcare professional to ensure safe and effective use. Potential side effects of ribavirin include anemia, fatigue, headache, insomnia, and gastrointestinal issues. Due to its potential teratogenic effects, ribavirin should not be used by pregnant women or those planning to become pregnant during treatment.